RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-5.97%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$522M
AUM Growth
-$108M
(-17%)
Cap. Flow
-$70.4M
Cap. Flow
% of AUM
-13.5%
Top 10 Holdings %
Top 10 Hldgs %
27.83%
Holding
119
New
12
Increased
37
Reduced
37
Closed
11
Top Buys
| 1 |
Gilead Sciences
GILD
|
$18.6M |
| 2 |
Medtronic
MDT
|
$15.3M |
| 3 |
Pfizer
PFE
|
$10.8M |
| 4 |
Elevance Health
ELV
|
$8.38M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$5.42M |
Top Sells
| 1 |
SHPG
Shire pic
SHPG
|
$26.6M |
| 2 |
CELG
Celgene Corp
CELG
|
$10.8M |
| 3 |
UnitedHealth
UNH
|
$8.8M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$8.56M |
| 5 |
Merck
MRK
|
$7.65M |
Sector Composition
| 1 | Healthcare | 94.79% |
| 2 | Financials | 1.61% |
| 3 | Technology | 0.16% |
| 4 | Energy | 0.11% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AET
26
DELISTED
Aetna Inc
AET
| $7.69M | 1.47% |
62,000
+20,000
| +48% | +$2.48M |
|
|
ESRX
27
DELISTED
Express Scripts Holding Company
ESRX
| $7.64M | 1.46% |
111,000
| – | – |
|
28
AbbVie
ABBV
$374B
| $7.2M | 1.38% |
115,000
+5,000
| +5% | +$313K |
|
29
Edwards Lifesciences
EW
$47.7B
| $6.56M | 1.26% |
210,000
+45,000
| +27% | +$1.41M |
|
|
NVRO
30
DELISTED
NEVRO CORP.
NVRO
| $6.49M | 1.24% |
89,314
+40,014
| +81% | +$2.91M |
|
31
Hologic
HOLX
$14.7B
| $6.42M | 1.23% |
160,000
-20,000
| -11% | -$802K |
|
32
Thermo Fisher Scientific
TMO
$183B
| $6.35M | 1.22% |
45,000
+20,000
| +80% | +$2.82M |
|
33
Supernus Pharmaceuticals
SUPN
$2.52B
| $6.31M | 1.21% |
250,000
-20,000
| -7% | -$505K |
|
34
Xencor
XNCR
$594M
| $5.92M | 1.14% |
225,000
| – | – |
|
35
Jazz Pharmaceuticals
JAZZ
$7.99B
| $5.55M | 1.06% |
50,920
-9,080
| -15% | -$990K |
|
|
ZLTQ
36
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $5.44M | 1.04% |
125,000
-35,000
| -22% | -$1.52M |
|
37
Cencora
COR
$57.2B
| $5.32M | 1.02% |
68,000
+15,000
| +28% | +$1.17M |
|
38
DexCom
DXCM
$30.9B
| $5.06M | 0.97% |
339,200
+79,200
| +30% | +$1.18M |
|
39
Alnylam Pharmaceuticals
ALNY
$58.6B
| $5.05M | 0.97% |
135,000
+5,000
| +4% | +$187K |
|
40
Nektar Therapeutics
NKTR
$543M
| $5.03M | 0.96% |
27,333
+1,333
| +5% | +$245K |
|
|
ENDP
41
DELISTED
Endo International plc
ENDP
| $4.94M | 0.95% |
300,200
-60,000
| -17% | -$988K |
|
|
ARRY
42
DELISTED
Array Biopharma Inc
ARRY
| $4.84M | 0.93% |
550,000
| – | – |
|
43
Vertex Pharmaceuticals
VRTX
$102B
| $4.79M | 0.92% |
65,013
-15,000
| -19% | -$1.11M |
|
44
Cardinal Health
CAH
$36B
| $4.68M | 0.9% |
65,000
+10,000
| +18% | +$720K |
|
45
Iovance Biotherapeutics
IOVA
$800M
| $4.52M | 0.87% |
650,000
| – | – |
|
|
ITCI
46
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $4.38M | 0.84% |
290,000
+155,000
| +115% | +$2.34M |
|
|
RVNC
47
DELISTED
Revance Therapeutics, Inc.
RVNC
| $4.35M | 0.83% |
210,000
| – | – |
|
48
Alkermes
ALKS
$4.95B
| $4.2M | 0.81% |
75,599
-100,000
| -57% | -$5.56M |
|
|
NXTM
49
DELISTED
NxStage Medical Inc.
NXTM
| $4.17M | 0.8% |
158,901
+13,601
| +9% | +$357K |
|
50
BioMarin Pharmaceuticals
BMRN
$11.3B
| $4.14M | 0.79% |
50,000
-90,000
| -64% | -$7.46M |
|